Skip to main content
Daniel Judge, MD, Cardiology, Charleston, SC

DanielJudgeMD

Cardiology Charleston, SC

Heart Failure & Transplantation

Cardiology Fellowship Director; Director of Cardiovascular Genetics

Dr. Judge is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Judge's full profile

Already have an account?

  • Office

    171 Ashley Ave
    Charleston, SC 29425
    Phone+1 843-792-1414

Summary

  • I am a board-certified specialist in Advanced Heart Failure & Transplant Cardiology, also boarded in Cardiovascular Disease. I direct the Cardiovascular Genetics program at Medical University of South Carolina, and I am also the Fellowship Program Director for Cardiovascular Disease at MUSC in Charleston, SC.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Cardiovascular Disease, 1996 - 2000
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1993 - 1996
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1992

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 2018 - 2025
  • MD State Medical License
    MD State Medical License 1996 - 2018
  • American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
  • American Board of Internal Medicine Cardiovascular Disease

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • With Post Hoc Analysis, BridgeBio Touts Case for Acoramidis as FDA Decision Date Draws Near
    With Post Hoc Analysis, BridgeBio Touts Case for Acoramidis as FDA Decision Date Draws NearSeptember 30th, 2024
  • BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-Related Hospitalization Events
    BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-Related Hospitalization EventsSeptember 27th, 2024